



The Place of Targeted Alpha Therapy in Optimizing Overall Survival in mCRPC Today and in the Future

Lunch Symposium
9 September 2017,
13:00–14:30

Alicante Auditorium, Hall 4
IFEMA, Feria de Madrid
Madrid, Spain

Chair:

Johann de Bono, MD, PhD
*Institute of Cancer Research and Royal Marsden,
London, United Kingdom*

Presenters:

Nicholas D. James, MD, PhD
*University of Birmingham,
Birmingham, United Kingdom*

Aurelius Omlin, MD
*Kantonsspital St. Gallen,
St. Gallen, Switzerland*

Joe O'Sullivan, MD
*Queen's University Belfast,
Belfast, United Kingdom*

Agenda

-
- | | |
|--------------------|---|
| 13:00–13:05 | Introduction
Johann de Bono, MD, PhD
<i>Institute of Cancer Research and Royal Marsden, London, United Kingdom</i> |
|--------------------|---|
-
- | | |
|--------------------|---|
| 13:05–13:25 | The Evolving Landscape of Treating Advanced Prostate Cancer
Nicholas D. James, MD, PhD
<i>University of Birmingham, Birmingham, United Kingdom</i> |
|--------------------|---|
-
- | | |
|--------------------|--|
| 13:25–13:55 | Case Studies in mCRPC – Navigating the Increasingly Busy Waters
Aurelius Omlin, MD
<i>Kantonsspital St. Gallen, St. Gallen, Switzerland</i>
Joe O'Sullivan, MD
<i>Queen's University Belfast, Belfast, United Kingdom</i> |
|--------------------|--|
-
- | | |
|--------------------|---|
| 13:55–14:15 | The Future of Targeted Alpha Therapy
Johann de Bono, MD, PhD
<i>Institute of Cancer Research and Royal Marsden, London, United Kingdom</i> |
|--------------------|---|
-
- | | |
|--------------------|---|
| 14:15–14:30 | Panel Discussion
Johann de Bono, MD, PhD
<i>Institute of Cancer Research and Royal Marsden, London, United Kingdom</i> |
|--------------------|---|
-